Dar? Bioscience, Inc. - SIC # 2834 - PHARMACEUTICAL PREPARATIONS

Ticker Exchange SIC # Website Latest Ticker
DARE Nasdaq 2834 darebioscience.com

Select one of the four (4) financial statement analysis reports below to view the ratio analysis report for your selected company:

Financial Analysis - Public Company vs Industry Ratio Analysis
Financial Analysis - Public Company
Industry Ratios Analysis
Public Company vs Public Company

Latest Headlines for Dar? Bioscience, Inc.

Daré Bioscience to Showcase Leadership in Women's Health Innovation at BIO International Convention 2026 - Jun 18th, 2026 7:20 am
Daré Bioscience Announces the Upcoming Launch of Flora Sync LF5™ Vaginal Probiotic Capsules - Jun 4th, 2026 6:00 am
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-HPV, its Novel Investigational Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - May 26th, 2026 6:00 am
Daré Bioscience Initiates Phase 2 Study of DARE-HPV, a Novel Pharmacologic Treatment for Persistent High-Risk HPV Infection with No FDA-Approved Therapies - May 18th, 2026 6:00 am
Dare Bioscience Inc (DARE) Q1 2026 Earnings Call Highlights: Strategic Milestones and Financial ... - May 14th, 2026 11:03 pm
Daré Bioscience Reports First Quarter 2026 Financial Results and Provides Business Update - May 14th, 2026 2:01 pm
Orchestra BioMed Holdings, Inc. (OBIO) Reports Q1 Loss, Lags Revenue Estimates - May 12th, 2026 3:40 pm
Positive Interim Phase 3 Results Highlight Potential of Ovaprene®, Novel Hormone-Free Contraceptive - May 12th, 2026 6:00 am
Daré Bioscience to Host First Quarter 2026 Financial Results and Company Update Conference Call and Webcast on May 14, 2026 - May 7th, 2026 6:00 am
Dare Bioscience, Inc. (DARE) Reports Q4 Loss, Lags Revenue Estimates - Mar 26th, 2026 3:20 pm
Daré Bioscience Reports Full Year 2025 Financial Results and Provides Business Update - Mar 26th, 2026 2:01 pm
On National Viagra Day, Women Finally Claim Their Turn: - Mar 23rd, 2026 6:00 am
Daré Bioscience to Host Full Year 2025 Financial Results and Company Update Conference Call and Webcast on March 26, 2026 - Mar 20th, 2026 6:00 am
Daré Bioscience Receives NIH Funding Award Notice to Advance DARE-PTB1, its Novel Intravaginal Ring for Prevention of Preterm Birth - Mar 16th, 2026 6:00 am
Daré Bioscience Participates in Virtual Investor “What This Means” Segment - Mar 12th, 2026 6:00 am
Dianthus Therapeutics, Inc. (DNTH) Reports Q4 Loss, Misses Revenue Estimates - Mar 9th, 2026 6:25 am
uniQure (QURE) Reports Q4 Loss, Misses Revenue Estimates - Mar 2nd, 2026 6:20 am
Daré Bioscience Announces FDA Clearance of IND for Phase 2 Clinical Study of DARE-HPV, a Potential Treatment for Persistent High-Risk HPV Infection, the Most Common Cause of Cervical Cancer - Feb 23rd, 2026 6:00 am
Telehealth Now Available for DARE to PLAY™ Sildenafil Cream: First Evidence-Based Topical Arousal Cream for Women - Feb 11th, 2026 6:00 am
Companies Like Daré Bioscience (NASDAQ:DARE) Are In A Position To Invest In Growth - Jan 20th, 2026 3:48 am